|
Synonyms: compound 352 [WO2023141432] | MXE-829 | MXE829 | MZE829
Compound class:
Synthetic organic
Comment: Alcedaplin (MXE829) is an apolipoprotein L1 (APOL1) inhibitor/modulator that is proposed to treat APOL1-associated nephropathy, particularly in individuals with a high-risk APOL1 genotype [1]. It is designed to inhibit both APOL1 pore formation and channel function.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Lee PST, Ewing JA, Reid AN, Sinz CJ, Zhang B, Bronner SM, Morgans DJ, Hoek M, Assimon VA, Ziebenhaus C et al.. (2023)
Apol1 inhibitors and methods of use. Patent number: WO2023141432A2. Assignee: Maze Therapeutics Inc. Priority date: 17/01/2023. Publication date: 27/07/2023. |